Tamoxifen in the Prevention of Breast Cancer in Hodgkin's Disease Survivors

Completed · Not applicable

Conditions studied: Hodgkin's Disease, Breast Cancer

In brief

The purpose of this study is determine whether or not tamoxifen reduces the chance of Hodgkin's Disease survivors developing breast cancer.

Key facts

Study ID

NCT00165308

Run by

Dana-Farber Cancer Institute

People needed

29

Starts

2001-04-01

Expected to finish

2009-06-01

Last updated by the study team

2014-07-09

Who can join

Age: 18 and older, up to 35. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Females diagnosed with Hodgkin's Disease at age < 35 years
• > 5 years from mantle or chest radiation
• Current age > 30 years
• Has completed childbearing
• Willingness to discontinue use of oral contraceptives or other hormonal contraception for duration of the study

You may not qualify if…

• History of secondary malignancy after Hodgkin's disease, except thyroid cancer of basal cell cancer
• Recurrence of Hodgkin's disease in the 5 years before study entry
• Current participation in any other cancer prevention study
• Current or prior use of tamoxifen
• Current use of coumadin
• History of deep venous thrombosis, pulmonary embolism, or a condition known to be associated with hypercoagulability
• History of cerebrovascular accident
• History of macular degeneration
• Current use of chemotherapy for benign disease

Where it is running

• Massachusetts General Hospital — Boston, Massachusetts, United States
• Dana-Farber Cancer Institute — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.